Ikarian Capital’s Adverum Biotechnologies ADVM Stock Holding History

Ikarian Capital’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,284	Closed	-$342K	–	175
2020 Q2	$477K	Buy	+2,284	New	+$405K	0.04%	136

Other funds holding ADVM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ikarian Capital's ADVM Position: Q3 2020 in Review

Ikarian Capital sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 2,284 shares — an estimated $342K sold.

Ikarian Capital first reported a position in ADVM in Q2 2020 and held it in 1 quarter. The position peaked at $477K in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

Ikarian Capital reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
Ikarian Capital sold 2,284 Adverum Biotechnologies shares in Q3 2020, an estimated $342K.
Ikarian Capital first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 1 quarter.
Ikarian Capital's Adverum Biotechnologies position peaked at $477K in Q2 2020.
160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.